Advisors Asset Management, Inc. Bluebird Bio, Inc. Transaction History

Advisors Asset Management, Inc.

$5.28 Billion
Q3 2024

A detailed history of Advisors Asset Management, Inc. transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 16,718 shares of BLUE stock, worth $138,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,718

Previous 19,777 15.47%

Holding current value

$138,090

Previous $19,000 57.89%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.47 - $1.35 $1,437 - $4,129	-3,059 Reduced 15.47%	16,718 $8,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $7 - $11	-9 Reduced 0.05%	19,777 $19,000
Q1 2024 May 14, 2024	SELL	$0.91 - $1.75 $860 - $1,655	-946 Reduced 4.56%	19,786 $25,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $733 - $2,685	556 Added 2.76%	20,732 $28,000
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $1,464 - $2,640	-525 Reduced 2.54%	20,176 $66,000
Q1 2023 May 12, 2023	BUY	$3.14 - $8.22 $10,349 - $27,093	3,296 Added 18.94%	20,701 $65,000
Q4 2022 Feb 13, 2023	BUY	$5.77 - $8.49 $100,426 - $147,768	17,405 New	17,405 $120,000
Q1 2021 May 07, 2021	SELL	$16.59 - $33.89 $49,770 - $101,670	-3,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$27.5 - $37.92 $962 - $1,327	-35 Reduced 1.15%	3,000 $130,000
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $1,859 - $2,362	-54 Reduced 1.75%	3,035 $164,000
Q2 2020 Aug 12, 2020	SELL	$27.12 - $45.97 $759 - $1,287	-28 Reduced 0.9%	3,089 $189,000
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $33,301 - $80,835	-1,273 Reduced 29.0%	3,117 $143,000
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $46,396 - $60,929	-988 Reduced 18.37%	4,390 $385,000
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $187,627 - $293,730	-3,155 Reduced 36.97%	5,378 $494,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $67,421 - $93,531	-889 Reduced 9.44%	8,533 $1.09 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $174,761 - $282,346	-2,712 Reduced 22.35%	9,422 $1.48 Million
Q4 2018 Jan 31, 2019	SELL	$59.1 - $93.26 $119,086 - $187,918	-2,015 Reduced 14.24%	12,134 $1.2 Million
Q3 2018 Nov 15, 2018	BUY	$88.86 - $117.49 $31,012 - $41,004	349 Added 2.53%	14,149 $2.07 Million
Q2 2018 Aug 22, 2018	SELL	$99.64 - $127.59 $4.53 Million - $5.8 Million	-45,427 Reduced 76.7%	13,800 $2.17 Million
Q2 2018 Aug 15, 2018	BUY	$99.64 - $127.59 $4.14 Million - $5.3 Million	41,522 Added 234.52%	59,227 $2.17 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $3,385 - $4,830	32 Added 0.18%	17,705 $3.56 Million
Q4 2017 Feb 13, 2018	BUY	$81.25 - $130.7 $84,256 - $135,535	1,037 Added 6.23%	17,673 $3.15 Million
Q3 2017 Nov 07, 2017	BUY	$57.74 - $91.42 $960,562 - $1.52 Million	16,636	16,636 $2.29 Million

Others Institutions Holding BLUE

# of Institutions

146

Shares Held

63.3M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $637M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.

Account

Advisors Asset Management, Inc. Bluebird Bio, Inc. Transaction History